Researchers at Boston-based Dana-Farber Cancer Institute have developed an online tool designed to better predict when smoldering multiple myeloma is most likely to progress to active cancer, offering clinicians more precise insight into when treatment may be needed.
Smoldering multiple myeloma is an early, asymptomatic condition that can develop into multiple myeloma.
The model, called PANGEA-SMM, uses routinely collected lab data to track how a patient’s disease changes over time rather than relying on a single set of test results. By continuously updating risk based on trends in those markers, the tool can flag when a patient is more likely to need treatment.
Researchers said the model outperformed existing risk assessment tools by more accurately identifying patients at high risk of progression, while also reducing unnecessary treatment for those with stable disease. The approach also allows clinicians to monitor patients without relying as heavily on invasive procedures.
To build the tool, researchers analyzed data from more than 2,300 patients with smoldering multiple myeloma across seven international centers, identifying key lab changes tied to disease progression. The model was then validated against commonly used risk assessment approaches.
The tool is available for free online and can be used during routine follow-up care.
At the Becker's Perioperative Summit, taking place October 29–31 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
